{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:31:07Z","timestamp":1793662267007,"version":"4.5.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>Prostate cancer (PCa) lacks precise diagnostic tools, necessitating noninvasive biomarkers. MicroRNAs (miRNAs) show promise due to fluid stability and oncogenic regulation. Using 2-sample Mendelian randomization (MR), we analyzed plasma miRNA expression quantitative trait loci (eQTLs) from discovery and validation cohorts. Cis-acting eQTLs served as instrumental variables, with causal effects assessed via inverse-variance weighted (IVW) and MR-Egger regression. Functional and survival analyses leveraged The Cancer Genome Atlas (TCGA)-PRAD data and bioinformatics tools. Five miRNAs (hsa-miR-127-3p, -370-3p, -125a-5p, -433-3p, -99b-5p) were inversely associated with PCa risk (IVW <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05, FDR\u2005&lt;\u20050.1). Two (hsa-miR-125a-5p\/-99b-5p) were validated (OR\u2005=\u20050.992\u20130.9924, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). Their 553 target genes included 9 survival-linked genes (e.g., FOXM1, BTG2), enriched in basement membrane organization, glutathione metabolism, and senescence. hsa-miR-127-3p was downregulated in PCa (fold change\u2005=\u20050.7, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), with pan-cancer prognostic relevance. hsa-miR-125a-5p and -99b-5p are causal protective factors against PCa, modulating oncogenic pathways and survival. These miRNAs offer potential as noninvasive biomarkers and therapeutic targets, advancing precision oncology.<\/jats:p>","DOI":"10.1097\/md.0000000000043613","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T23:01:11Z","timestamp":1754089271000},"page":"e43613","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Mendelian randomization reveals causal circulatory microRNAs in prostate cancer pathogenesis and prognosis"],"prefix":"10.1097","volume":"104","author":[{"given":"Zhicheng","family":"Cong","sequence":"first","affiliation":[{"name":"Department of Urology, Zhejiang Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8023-962X","authenticated-orcid":false,"given":"Haiping","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhejiang Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250918","doi-asserted-by":"crossref","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019.","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"R2-20250918","doi-asserted-by":"crossref","first-page":"469580221095822","DOI":"10.1177\/00469580221095822","article-title":"Early detection of prostate cancer: self-reported knowledge and attitude of physicians in Jordan.","volume":"59","author":"Alqudah","year":"2022","journal-title":"Inquiry"},{"key":"R3-20250918","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.urolonc.2018.05.008","article-title":"Intratumor heterogeneity in prostate cancer.","volume":"36","author":"Yadav","year":"2018","journal-title":"Urol Oncol"},{"key":"R4-20250918","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/cells9020276","article-title":"miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis.","volume":"9","author":"Condrat","year":"2020","journal-title":"Cells Basel"},{"key":"R5-20250918","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/fon-2022-0891","article-title":"The role of miRNA in prostate cancer diagnosis, prognosis and treatment response: a narrative review.","volume":"19","author":"Vazquez-Urrutia","year":"2023","journal-title":"Future Oncol"},{"key":"R6-20250918","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function.","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"R7-20250918","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-0359","article-title":"OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer.","volume":"76","author":"Svoronos","year":"2016","journal-title":"Cancer Res"},{"key":"R8-20250918","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/pros.23714","article-title":"miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.","volume":"79","author":"Ghorbanmehr","year":"2019","journal-title":"Prostate"},{"key":"R9-20250918","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coemr.2020.02.002","article-title":"Oncogenic and tumor-suppressive microRNAs in prostate cancer.","volume":"10","author":"Zenner","year":"2020","journal-title":"Curr Opin Endocr Metab Res"},{"key":"R10-20250918","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/bjc.2017.50","article-title":"Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.","volume":"116","author":"Lin","year":"2017","journal-title":"Br J Cancer"},{"key":"R11-20250918","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1093\/nar\/gkw116","article-title":"Distribution of miRNA expression across human tissues.","volume":"44","author":"Ludwig","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"R12-20250918","doi-asserted-by":"crossref","first-page":"125094","DOI":"10.1155\/2015\/125094","article-title":"MicroRNAs as potential biomarkers in cancer: opportunities and challenges.","volume":"2015","author":"Lan","year":"2015","journal-title":"Biomed Res Int"},{"key":"R13-20250918","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2217\/fon-2018-0812","article-title":"Why have microRNA biomarkers not been translated from bench to clinic?","volume":"15","author":"Saliminejad","year":"2019","journal-title":"Future Oncol"},{"key":"R14-20250918","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13148-018-0492-1","article-title":"Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage.","volume":"10","author":"Wang","year":"2018","journal-title":"Clin Epigenetics"},{"key":"R15-20250918","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1373\/clinchem.2018.296681","article-title":"Independent validation of a diagnostic noninvasive 3-MicroRNA ratio model (uCaP) for prostate cancer in cell-free urine.","volume":"65","author":"Freds\u00f8e","year":"2019","journal-title":"Clin Chem"},{"key":"R16-20250918","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s40471-017-0128-6","article-title":"Recent developments in Mendelian randomization studies.","volume":"4","author":"Zheng","year":"2017","journal-title":"Curr Epidemiol Rep"},{"key":"R17-20250918","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.3390\/cells10123504","article-title":"Identifying putative causal links between MicroRNAs and severe COVID-19 using mendelian randomization.","volume":"10","author":"Li","year":"2021","journal-title":"Cells Basel"},{"key":"R18-20250918","doi-asserted-by":"crossref","first-page":"1385675","DOI":"10.3389\/fnins.2024.1385675","article-title":"Systematic genome-wide Mendelian randomization reveals the causal links between miRNAs and Parkinson\u2019s disease.","volume":"18","author":"Shi","year":"2024","journal-title":"Front Neurosci"},{"key":"R19-20250918","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1007\/s10072-023-06860-3","article-title":"Evaluating the causal association between microRNAs and amyotrophic lateral sclerosis.","volume":"44","author":"Zhu","year":"2023","journal-title":"Neurol Sci"},{"key":"R20-20250918","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/sim.3034","article-title":"Mendelian randomization: using genes as instruments for making causal inferences in epidemiology.","volume":"27","author":"Lawlor","year":"2008","journal-title":"Stat Med"},{"key":"R21-20250918","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1038\/ncomms7601","article-title":"Genome-wide identification of microRNA expression quantitative trait loci.","volume":"6","author":"Huan","year":"2015","journal-title":"Nat Commun"},{"key":"R22-20250918","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/cvr\/cvz030","article-title":"Genome-wide identification of circulating-miRNA expression quantitative trait loci reveals the role of several miRNAs in the regulation of cardiometabolic phenotypes.","volume":"115","author":"Nikpay","year":"2019","journal-title":"Cardiovasc Res"},{"key":"R23-20250918","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12935-020-01209-8","article-title":"miR-125a-5p post-transcriptionally suppresses GALNT7 to inhibit proliferation and invasion in cervical cancer cells via the EGFR\/PI3K\/AKT pathway.","volume":"20","author":"Cao","year":"2020","journal-title":"Cancer Cell Int"},{"key":"R24-20250918","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.2147\/OTT.S92314","article-title":"MicroRNA-125a-5p regulates cancer cell proliferation and migration through NAIF1 in prostate carcinoma.","volume":"8","author":"Fu","year":"2015","journal-title":"Onco Targets Ther"},{"key":"R25-20250918","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.4149\/neo_2020_191130N1234","article-title":"Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer.","volume":"67","author":"Li","year":"2020","journal-title":"Neoplasma"},{"key":"R26-20250918","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1590\/1806-9282.66.4.445","article-title":"miR-125a-5p inhibits cancer stem cells phenotype and epithelial to mesenchymal transition in glioblastoma.","volume":"66","author":"Zhu","year":"2020","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"R27-20250918","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1590\/1806-9282.66.5.706","article-title":"Manipulating miR-125a-5p to regulate cancer stem cells phenotype and epithelial to mesenchymal transition in glioblastoma.","volume":"66","author":"Sha","year":"2020","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"R28-20250918","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3390\/cancers16101933","article-title":"Combination of miR-99b-5p and enzalutamide or abiraterone synergizes the suppression of EMT-Mediated metastasis in prostate cancer.","volume":"16","author":"Waseem","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R29-20250918","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.3390\/ijms23179643","article-title":"Downregulation of miR-99b-5p and upregulation of nuclear mTOR cooperatively promotes the tumor aggressiveness and drug resistance in African American Prostate Cancer.","volume":"23","author":"Gujrati","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R30-20250918","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/TUB-211568","article-title":"MicroRNA-99b-5p targets mTOR\/AR axis, induces autophagy and inhibits prostate cancer cell proliferation.","volume":"44","author":"Niture","year":"2022","journal-title":"Tumour Biol"},{"key":"R31-20250918","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1007\/s12015-023-10606-1","article-title":"Exosomal miR-99b-5p Secreted from mesenchymal stem cells can retard the progression of colorectal cancer by targeting FGFR3.","volume":"19","author":"Ning","year":"2023","journal-title":"Stem Cell Rev Rep"},{"key":"R32-20250918","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ymthe.2022.01.004","article-title":"miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma.","volume":"30","author":"Holliday","year":"2022","journal-title":"Mol Ther"},{"key":"R33-20250918","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1134\/S0006297922050030","article-title":"Oxidative stress and redox-dependent signaling in prostate cancer.","volume":"87","author":"Kalinina","year":"2022","journal-title":"Biochemistry (Mosc)"},{"key":"R34-20250918","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cmdc.201700660","article-title":"A novel prodrug of a \u03b3-Glutamylcyclotransferase inhibitor suppresses cancer cell proliferation in vitro and inhibits tumor growth in a xenograft mouse model of prostate cancer.","volume":"13","author":"Ii","year":"2018","journal-title":"ChemMedChem"},{"key":"R35-20250918","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.acuro.2016.12.001","article-title":"Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts.","volume":"41","author":"Fernandez-Gomez","year":"2017","journal-title":"Actas Urol Esp"},{"key":"R36-20250918","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.7314\/APJCP.2015.16.15.6639","article-title":"Correlation between microvascular density and matrix metalloproteinase 11 expression in prostate cancer tissues: a preliminary study in Thailand.","volume":"16","author":"Kanharat","year":"2015","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:02:02Z","timestamp":1758232922000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":36,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043613","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}